ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
21 November 2022 - 10:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Daniel Char, JD, has been appointed Senior
Vice President and Chief Legal Officer.
"We are pleased to welcome Daniel to ImmunoGen to lead our Legal
team and join ImmunoGen's Executive Committee. With his deep
expertise advising on commercial, regulatory, compliance, and
corporate governance matters, Daniel will play an important role as
we increase the scale and complexity of the business as we build
momentum with the launch of ELAHERE™ (mirvetuximab
soravtansine-gynx) and advance the rest of our portfolio," said
Mark Enyedy, ImmunoGen's President and Chief Executive Officer.
"Daniel succeeds Joseph Kenny, who has served as our Acting General
Counsel and Vice President since March 2020 and will remain with
ImmunoGen serving in an Associate General Counsel capacity."
Mr. Char joins ImmunoGen from Evelo Biosciences where he served
as General Counsel and Secretary providing strategic counsel and
operational support on a broad range of business and legal issues,
including business development, commercialization, healthcare
fraud, and intellectual property. Prior to joining Evelo, Mr. Char
was Associate General Counsel and Assistant Secretary at
Smith+Nephew, after having served as General Counsel and Secretary
at Targanta Therapeutics, Senior Associate General Counsel at
Idenix Pharmaceuticals, and Associate General Counsel at Biogen.
Mr. Char holds a JD from Harvard Law School and a BA in Economics
from Tufts University.
"I am thrilled to join ImmunoGen during this transformational
period following the Company's first product approval, and I look
forward to working closely with the Executive Committee and Legal
team to support ELAHERE's successful launch," said Mr. Char. "As a
fully-integrated oncology company, ImmunoGen's growth will be
driven by both commercial execution and continued pipeline
advancement, and I am excited to contribute as the organization
evolves."
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
ABOUT ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)
ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC
comprising a folate receptor alpha-binding antibody, cleavable
linker, and the maytansinoid payload DM4, a potent tubulin
inhibitor designed to kill the targeted cancer cells. Please see
full Prescribing Information, including Boxed Warning for ELAHERE,
here.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These
statements include, but are not limited to, ImmunoGen's
expectations related to: ImmunoGen's growth and commercial efforts
in support of ELAHERE, the development of the mirvetuximab
soravtansine program, and ImmunoGen's product pipeline. Various
factors could cause ImmunoGen's actual results to differ materially
from those discussed or implied in the forward-looking statements,
and you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to:
the timing and outcome of the Company's preclinical and clinical
development processes; the difficulties inherent in the development
of novel pharmaceuticals, including uncertainties as to the timing,
expense, and results of preclinical studies, clinical trials, and
regulatory processes; the timing and outcome of the Company's
anticipated interactions with regulatory authorities; the risk that
we may not be able to obtain adequate prices and reimbursement for
any approved products, including the potential for delays or
additional difficulties for ELAHERE; the risk that the results of
the ongoing MIRASOL trial may fail to support full approval of
ELAHERE and, if so, that additional studies may be required; risks
and uncertainties associated with the scale and duration of the
COVID-19 pandemic and the resulting impact on ImmunoGen's industry
and business; and other factors as set forth in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February 28, 2022, Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission on May 6, 2022
and August 1, 2022, and other reports filed with the Securities and
Exchange Commission. The forward-looking statements in this press
release speak only as of the date of this press release. We
undertake no obligation to update any forward-looking statement,
whether as a result of new information, future developments, or
otherwise, except as may be required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221121005078/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com MEDIA CONTACTS
ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com OR FTI Consulting Robert
Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024